Background: The prevalence of adult obesity has increased in recent decades. It is important to predict the long-term effect of body weight, and changes in body weight, in middle age on longevity and Medicare costs in older ages.
Methods: The relationships between individuals' characteristics in middle age and subsequent Medicare costs and mortality were estimated from the linkage of the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study to Medicare administrative records (1991-2000) and mortality information (1971-2000). We predicted longevity and lifetime Medicare costs via simulation for 45-year-old persons by body weight in 1973 and changes in body weight between 1973 and 1983.
Results: Obese 45-year-olds had a smaller chance of surviving to age 65 and, if they did, incurred significantly higher average lifetime Medicare costs than normal-weight 45-year-olds ($163,000 compared with $117,000). Those who remained obese between ages 45 and 55 in 1973 to 1983 incurred significantly higher lifetime Medicare costs than those who maintained normal weight. Other weight change categories did not differ significantly from those who maintained normal weight in terms of life expectancy at age 65, but overweight and obese people who lost weight had less chance of surviving to age 65 and the lowest estimated life expectancies thereafter.
Conclusions: Chronic obesity in middle age increases lifetime Medicare costs relative to those who remained normal weight. As the survival of obese persons improves, it is possible that Medicare costs may rise substantially in the future to meet the health care needs of today's obese middle-aged population. Thus, active engagement by both the private and public sectors to prevent and to reduce obesity are critically needed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MLR.0b013e3181dbdb20 | DOI Listing |
Am J Manag Care
December 2024
Johns Hopkins Hospital, 1305 Dock St, Apt 310, Baltimore, MD 21231. Email:
Objectives: Although cardiac rehabilitation (CR) improves cardiovascular outcomes, adherence remains low. Higher patient-incurred out-of-pocket (OOP) spending may be a barrier to CR adherence. We evaluated the association between OOP spending for the first CR session and adherence.
View Article and Find Full Text PDFAm J Manag Care
December 2024
Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, 4306D Walker Building, Auburn University, Auburn, AL 36849-5506. Email:
Objectives: This study evaluated the uptake and costs of 3 biosimilars among Medicare and Medicaid populations for 2019 to 2022: rituximab-abbs (Truxima), rituximab-pvvr (Ruxience), and rituximab-arrx (Riabni).
Study Design: A retrospective, descriptive study.
Methods: Using the annually aggregated, product-level utilization and cost data of biologic and biosimilar rituximab products from CMS drug spending data, total claims and costs (reimbursement and out of pocket) for all rituximab products were identified and extracted from Medicare Part B, Medicare Part D, and Medicaid.
BMJ Open
December 2024
Health Services, University of Washington, Seattle, Washington, USA.
Introduction: Ineffective coordination during care transitions from hospitals to skilled nursing facilities (SNFs) costs Medicare US$2.8-US$3.4 billion annually and results in avoidable adverse events.
View Article and Find Full Text PDFCancer Med
January 2025
Department of Urology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Introduction: Oral targeted therapies are a standard of care for men with advanced prostate cancer. However, these therapies are expensive, which may be a barrier to some, particularly the most economically disadvantaged. Through investment in programs to assist this population, savings generated from the 340B program have the potential to mitigate barriers to initiating treatment with targeted therapies in these men.
View Article and Find Full Text PDFHealth Serv Res
December 2024
Department of Economics, College of Business, University of Louisville, Louisville, Kentucky, USA.
Objective: To examine the impact of medical and recreational cannabis laws on inpatient visits for asthma and by payer-type.
Study Setting And Design: Quasi-experimental difference-in-differences regression analysis was conducted while accounting for variations in cannabis laws implementation timing by states. Inpatient visits for asthma in states with a given type of cannabis law were compared with those in states that did not implement the specific law.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!